Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first‐line treatment of advanced non‐small cell lung cancer: a generic protocol

Información

DOI:
https://doi.org/10.1002/14651858.CD013009Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 26 abril 2018see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Cáncer de pulmón

Copyright:
  1. Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Nicholas LX Syn

    Correspondencia a: Department of Haematology‐Oncology, National University Cancer Institute, Singapore, Singapore

    [email protected]

  • Raheleh Roudi

    Oncopathology Research Center, Iran University of Medical Sciences, Teheran, Iran

  • Louis Zizhao Wang

    Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

  • Lingzhi Wang

    Cancer Science Institute of Singapore, Singapore, Singapore

  • Marie Loh

    Translational Laboratory in Genetic Medicine, Agency for Science, Technology and Research, Singapore, Singapore

  • Yiqing Huang

    Department of Haematology‐Oncology, National University Cancer Institute, Singapore, Singapore

  • Sai‐Hong Ignatius Ou

    Division of Hematology‐Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center, Irvine, USA

  • Richie Soong

    Department of Pathology, National University of Singapore, Singapore, Singapore

  • Alexander Drilon

    Early Drug Development Service, Memorial Sloan‐Kettering Cancer Center, New York, USA

  • Ian Wee

    Department of Haematology‐Oncology, National University Cancer Institute, Singapore, Singapore

Contributions of authors

Drafting the protocol: Nicholas Syn, Sai‐Hong Ignatius Ou, Marie Loh, Ian Wee, Louis Zizhao Wang, Lingzhi Wang, Yiqing Huang, Richie Soong, Alexander Drilon.

Developing and running the search strategy: Cochrane Lung Cancer Group Information Specialists (Francois Calais and Giorgio Maria Agazzi).

Obtaining copies of studies: Louis Zizhao Wang.

Selecting which studies to include: Nicholas Syn, Raheleh Roudi, Ian Wee, Sai‐Hong Ignatius Ou, Yiqing Huang, Richie Soong, Alexander Drilon.

Extracting data from studies: Nicholas Syn, Raheleh Roudi, Ian Wee.

Entering data into RevMan: Nicholas Syn, Raheleh Roudi.

Carrying out the analysis: Nicholas Syn, Ian Wee

Interpreting the analysis: Nicholas Syn, Sai‐Hong Ignatius Ou, Marie Loh, Ian Wee, Louis Zizhao Wang, Lingzhi Wang, Yiqing Huang, Richie Soong, Alexander Drilon.

Drafting the final review: Nicholas Syn, Sai‐Hong Ignatius Ou, Marie Loh, Ian Wee, Louis Zizhao Wang, Lingzhi Wang, Yiqing Huang, Richie Soong, Alexander Drilon.

Updating the review: Nicholas Syn, Sai‐Hong Ignatius Ou, Marie Loh, Ian Wee, Louis Zizhao Wang, Lingzhi Wang, Yiqing Huang, Richie Soong, Alexander Drilon.

Declarations of interest

Nicholas Syn: none known.

Raheleh Roudi: none known.

Louis Zizhao Wang: none known.

Lingzhi Wang: none known.

Marie Loh: none known.

Yiqing Huang: none known.

Sai‐Hong Ignatius Ou: none known.

Richie Soong: none known.

Alexander Drilon has received consulting fees/honoraria from AstraZeneca and Roche/Genetech. He has also received consulting fees/honoraria from Loxo Oncology/Bayer, Beigene, Ignyta, TP Therapeutics, and Blueprint Medicines, and royalties from Lippincott.

Ian Wee: none known.

Acknowledgements

We thank the Cochrane Lung Cancer Group, especially Corynne Marchal for editorial support, and Francois Calais and Giorgio Maria Agazzi for developing and executing the search strategy.

We also thank the following individuals for feedback on the review protocol: Fergus Macbeth, Jean‐Paul Sculier, Kwun Fong, Cheryl Ho and Nicolas Girard, as well as sign‐off editor Virginie Westeel.

Version history

Published

Title

Stage

Authors

Version

2018 Apr 26

Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first‐line treatment of advanced non‐small cell lung cancer: a generic protocol

Protocol

Nicholas LX Syn, Raheleh Roudi, Louis Zizhao Wang, Lingzhi Wang, Marie Loh, Yiqing Huang, Sai‐Hong Ignatius Ou, Richie Soong, Alexander Drilon, Ian Wee

https://doi.org/10.1002/14651858.CD013009

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Mechanisms by which chemotherapy synergises with immunotherapy. Figure drawn by Nicholas Syn.
Figuras y tablas -
Figure 1

Mechanisms by which chemotherapy synergises with immunotherapy. Figure drawn by Nicholas Syn.

Ir a la figura del protocoloAbrir en una pestaña nueva